These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 21523432)

  • 1. [Study to castrate-resistant prostate cancer: AUO study AP 60/10].
    Rexer H
    Urologe A; 2011 May; 50(5):607-8. PubMed ID: 21523432
    [No Abstract]   [Full Text] [Related]  

  • 2. [AUO study AP 59/10: first-line therapy of castration-resistant prostate cancer].
    Rexer H
    Urologe A; 2011 Jun; 50(6):722-4. PubMed ID: 21584827
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of IMiDs alone or in combination in prostate cancer.
    Nabhan C; Petrylak DP
    Clin Genitourin Cancer; 2012 Sep; 10(3):141-6. PubMed ID: 22608152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MAINSAIL trial: an expected failure.
    Boccardo F
    Lancet Oncol; 2015 Apr; 16(4):355-6. PubMed ID: 25743936
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemotherapy in patients with castration-resistant prostate cancer.
    Meulenbeld HJ; Hamberg P; de Wit R
    Eur J Cancer; 2009 Sep; 45 Suppl 1():161-71. PubMed ID: 19775615
    [No Abstract]   [Full Text] [Related]  

  • 6. Urological cancer: Is docetaxel the 'black widow' of mCRPC drugs?
    Liaw BC; Oh WK
    Nat Rev Clin Oncol; 2015 Jun; 12(6):316-8. PubMed ID: 25917253
    [No Abstract]   [Full Text] [Related]  

  • 7. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
    Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Docetaxel-based combination chemotherapy for castration-resistant prostate cancer].
    Urakami S; Shiina H; Igawa M
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():531-7. PubMed ID: 22208039
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
    Chi KN; Hotte SJ; Yu EY; Tu D; Eigl BJ; Tannock I; Saad F; North S; Powers J; Gleave ME; Eisenhauer EA
    J Clin Oncol; 2010 Sep; 28(27):4247-54. PubMed ID: 20733135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
    Buonerba C; Federico P; D'Aniello C; Rescigno P; Cavaliere C; Puglia L; Ferro M; Altieri V; Perdonà S; De Placido S; Di Lorenzo G
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1455-61. PubMed ID: 21365219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer.
    Mountzios I; Bournakis E; Efstathiou E; Varkaris A; Wen S; Chrisofos M; Deliveliotis C; Alamanis C; Anastasiou I; Constantinides C; Karadimou A; Tsiatas M; Papadimitriou C; Bamias A; Dimopoulos MA
    Urology; 2011 Mar; 77(3):682-7. PubMed ID: 21256546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.
    Sridhar SS; Canil CM; Chi KN; Hotte SJ; Ernst S; Wang L; Chen EX; Juhasz A; Yen Y; Murray P; Zwiebel JA; Moore MJ
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):927-33. PubMed ID: 20602233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxib.
    Marschner N; Zaiss M
    Onkologie; 2012; 35(5):279-82. PubMed ID: 22868509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-based treatment for castration-resistant prostate cancer.
    Seruga B; Tannock IF
    J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; George DJ
    Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy.
    de Wit R
    Eur J Cancer; 2005 Mar; 41(4):502-7. PubMed ID: 15737553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New treatment approach to hormone-refractory prostate carcinoma].
    Rexer H
    Urologe A; 2007 Jul; 46(7):786-8. PubMed ID: 17598082
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol 2012;61:363-9.
    Shen Y; Ye D
    Eur Urol; 2012 Feb; 61(2):e3; author reply e4-5. PubMed ID: 21824719
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug combination can extend life for men with prostate cancer.
    FDA Consum; 2004; 38(4):3. PubMed ID: 15346560
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
    Scher HI; Jia X; Chi K; de Wit R; Berry WR; Albers P; Henick B; Waterhouse D; Ruether DJ; Rosen PJ; Meluch AA; Nordquist LT; Venner PM; Heidenreich A; Chu L; Heller G
    J Clin Oncol; 2011 Jun; 29(16):2191-8. PubMed ID: 21483004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.